InvestorsHub Logo
Followers 1041
Posts 116560
Boards Moderated 12
Alias Born 06/10/2006

Re: None

Wednesday, 11/10/2021 1:21:19 PM

Wednesday, November 10, 2021 1:21:19 PM

Post# of 167
Upcoming Milestones

UBX1325 Phase 2a proof of concept study in DME had a first patient dosed in June 2021 and is actively recruiting patients, with information about that trial available here. Twelve-week safety and efficacy data are expected in the first half of 2022.

UBX1325 Phase 2 proof of concept study in AMD is expected to initiate in the first half of 2022, with twelve-week safety and efficacy data expected in the second half of 2022.

UBX2050 (Tie2 mAb) and UBX2089 (alpha-Klotho) expected to enter IND-enabling studies in 2022.

It is understood that all posts on the site are to be considered opinions. They do not need to indicate this in their posts.

Readers determine the veracity of the posts they read and the credibility of other Users


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent UBX News